This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEastWest Bioscience（EAST.H）株式概要垂直統合型ウェルネス企業であるイーストウエスト・バイオサイエンス社は、カナダと米国でヘンプ栄養製品の製造・販売に従事している。 詳細EAST.H ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析意味のある時価総額がありません ( CA$3M )最新の財務報告は1年以上前のものである 株式の流動性は非常に低い すべてのリスクチェックを見るEAST.H Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW492,520 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG492,520 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.02578.6% 割高 内在価値ディスカウントEst. Revenue$PastFuture-4m2m2016201920222025202620282031Revenue CA$703.1kEarnings CA$102.9kAdvancedSet Fair ValueView all narrativesEastWest Bioscience Inc. 競合他社Craftport CannabisSymbol: CNSX:CFTMarket cap: CA$2.7mCaptor CapitalSymbol: CNSX:CPTRMarket cap: CA$767.1kOptima Medical InnovationsSymbol: CNSX:OMICMarket cap: CA$2.1mWest Island BrandsSymbol: CNSX:WIBMarket cap: CA$2.0m価格と性能株価の高値、安値、推移の概要EastWest Bioscience過去の株価現在の株価CA$0.02552週高値CA$0.02552週安値CA$0.025ベータ01ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化25.00%5年間の変化-28.57%IPOからの変化-85.71%最新ニュースBoard Change • Jul 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Sep 08Is EastWest Bioscience (CVE:EAST) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Jun 30Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.006 loss per share (down from CA$0.002 loss in 3Q 2021). Net loss: CA$560.9k (loss widened 269% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • May 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.最新情報をもっと見るRecent updatesBoard Change • Jul 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Sep 08Is EastWest Bioscience (CVE:EAST) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Jun 30Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.006 loss per share (down from CA$0.002 loss in 3Q 2021). Net loss: CA$560.9k (loss widened 269% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • May 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 02Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0.021 (up from CA$0.002 loss in 2Q 2021). Revenue: CA$235.4k (down 33% from 2Q 2021). Net income: CA$2.09m (up CA$2.30m from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Reported Earnings • Dec 05Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.017 loss per share (down from CA$0.014 loss in FY 2020). Revenue: CA$1.06m (up 15% from FY 2020). Net loss: CA$1.61m (loss widened 42% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 01Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$311.0k (up 124% from 3Q 2020). Net loss: CA$151.9k (loss narrowed 60% from 3Q 2020).Reported Earnings • Jan 16First quarter 2021 earnings released: CA$0.003 loss per shareThe company reported a soft first quarter result with weaker revenues and control over expenses, though losses reduced. First quarter 2021 results: Revenue: CA$172.2k (down 56% from 1Q 2020). Net loss: CA$311.4k (loss narrowed 27% from 1Q 2020).お知らせ • Jan 08Eastwest Bioscience Inc. Announces Executive ChangesEastwest Bioscience Inc. announced that the Corporation has appointed Ciska Asriel to serve as interim Chief Financial Officer, in addition to her regular duties as Chief Operating Officer. Ms. Asriel will replace Paul Marjerrison as Chief Financial Officer and the Corporation would like to thank Mr. Marjerrison for his dedicated service. Ciska Asriel is the current Chief Operating Officer of the Corporation. Before joining EastWest as a Co-Founder and Chief Operating Officer, Ms. Asriel worked as a consultant, senior analyst and project manager for small companies as well as major firms including Deloitte. Her career experience is with project management, data analysis and business development in industry sectors including information technology, retail franchise operations, automotive franchise operations and insurance, global shipping and most recently software engineering and the development of mobile applications. Ms. Asriel's appointment is subject to approval by the TSX Venture Exchange.Reported Earnings • Dec 31Full year 2020 earnings released: CA$0.014 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$922.8k (down 34% from FY 2019). Net loss: CA$1.13m (loss narrowed 69% from FY 2019).お知らせ • Jul 30EastWest Bioscience Inc. (TSXV:EAST) completed the acquisition of remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp.EastWest Bioscience Inc. (TSXV:EAST) agreed to acquire remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. for CAD 0.08 million on December 18, 2019. Under the terms of the agreement, EastWest Bioscience Inc. will pay 2.77 million shares as consideration. EastWest Bioscience Inc. already hold 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. Post acquisition, EastWest Bioscience Inc. will hold 100% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. The transaction is subject to approval of the TSX Venture Exchange. EastWest Bioscience Inc. (TSXV:EAST) completed the acquisition of remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. on February 11, 2020.お知らせ • Jun 19EastWest Bioscience Inc. announced that it expects to receive CAD 0.1 million in fundingEastWest Bioscience Inc. (TSXV:EAST) announced a private placement of up to 2,000,000 common shares at an issue price of CAD 0.05 per share for gross proceeds of up to CAD 100,000 on June 18, 2020. All securities issued in the transaction have a hold period of 4 months. The transaction is subject to approval from TSX Venture Exchange.株主還元EAST.HCA PharmaceuticalsCA 市場7D0%-4.2%-0.7%1Yn/a33.1%27.4%株主還元を見る業界別リターン: EAST.HがCanadian Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: EAST.H Canadian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is EAST.H's price volatile compared to industry and market?EAST.H volatilityEAST.H Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.8%Market Average Movement9.5%10% most volatile stocks in CA Market16.5%10% least volatile stocks in CA Market3.6%安定した株価: EAST.Hの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のEAST.Hのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2016n/aRodney Gelineauwww.eastwestbioscience.com垂直統合型ウェルネス企業であるイーストウエスト・バイオサイエンス社は、カナダと米国でヘンプ栄養製品の製造・販売に従事している。同社はまた、フランチャイズ店舗とオンラインeコマース・プラットフォームを通じてサプリメントとウェルネス製品を販売するサングスターズ・ヘルスセンター店舗も運営している。さらに、不動産管理事業にも携わっている。同社は2016年に設立され、カナダのペンティクトンに本社を置いている。もっと見るEastWest Bioscience Inc. 基礎のまとめEastWest Bioscience の収益と売上を時価総額と比較するとどうか。EAST.H 基礎統計学時価総額CA$2.52m収益（TTM）CA$108.55k売上高(TTM)CA$703.10k0.0xPER（株価収益率0.0xP/SレシオEAST.H は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EAST.H 損益計算書（TTM）収益CA$703.10k売上原価CA$293.78k売上総利益CA$409.33kその他の費用CA$300.78k収益CA$108.55k直近の収益報告Apr 30, 2022次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%EAST.H の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/12 09:42終値2024/07/15 00:00収益2022/04/30年間収益2021/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EastWest Bioscience Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Jul 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Sep 08Is EastWest Bioscience (CVE:EAST) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Jun 30Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.006 loss per share (down from CA$0.002 loss in 3Q 2021). Net loss: CA$560.9k (loss widened 269% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • May 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jul 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Sep 08Is EastWest Bioscience (CVE:EAST) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Jun 30Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 3Q 2021)Third quarter 2022 results: CA$0.006 loss per share (down from CA$0.002 loss in 3Q 2021). Net loss: CA$560.9k (loss widened 269% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • May 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Paul Mandl was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 02Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0.021 (up from CA$0.002 loss in 2Q 2021). Revenue: CA$235.4k (down 33% from 2Q 2021). Net income: CA$2.09m (up CA$2.30m from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Reported Earnings • Dec 05Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: CA$0.017 loss per share (down from CA$0.014 loss in FY 2020). Revenue: CA$1.06m (up 15% from FY 2020). Net loss: CA$1.61m (loss widened 42% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 01Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$311.0k (up 124% from 3Q 2020). Net loss: CA$151.9k (loss narrowed 60% from 3Q 2020).
Reported Earnings • Jan 16First quarter 2021 earnings released: CA$0.003 loss per shareThe company reported a soft first quarter result with weaker revenues and control over expenses, though losses reduced. First quarter 2021 results: Revenue: CA$172.2k (down 56% from 1Q 2020). Net loss: CA$311.4k (loss narrowed 27% from 1Q 2020).
お知らせ • Jan 08Eastwest Bioscience Inc. Announces Executive ChangesEastwest Bioscience Inc. announced that the Corporation has appointed Ciska Asriel to serve as interim Chief Financial Officer, in addition to her regular duties as Chief Operating Officer. Ms. Asriel will replace Paul Marjerrison as Chief Financial Officer and the Corporation would like to thank Mr. Marjerrison for his dedicated service. Ciska Asriel is the current Chief Operating Officer of the Corporation. Before joining EastWest as a Co-Founder and Chief Operating Officer, Ms. Asriel worked as a consultant, senior analyst and project manager for small companies as well as major firms including Deloitte. Her career experience is with project management, data analysis and business development in industry sectors including information technology, retail franchise operations, automotive franchise operations and insurance, global shipping and most recently software engineering and the development of mobile applications. Ms. Asriel's appointment is subject to approval by the TSX Venture Exchange.
Reported Earnings • Dec 31Full year 2020 earnings released: CA$0.014 loss per shareThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$922.8k (down 34% from FY 2019). Net loss: CA$1.13m (loss narrowed 69% from FY 2019).
お知らせ • Jul 30EastWest Bioscience Inc. (TSXV:EAST) completed the acquisition of remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp.EastWest Bioscience Inc. (TSXV:EAST) agreed to acquire remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. for CAD 0.08 million on December 18, 2019. Under the terms of the agreement, EastWest Bioscience Inc. will pay 2.77 million shares as consideration. EastWest Bioscience Inc. already hold 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. Post acquisition, EastWest Bioscience Inc. will hold 100% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. The transaction is subject to approval of the TSX Venture Exchange. EastWest Bioscience Inc. (TSXV:EAST) completed the acquisition of remaining 50% stake in 1123573 BC Ltd. and Orchard Valley Naturals Ltd. from Darryl Sangster, Aquila Health Corp. and Sangster's Real Estate Corp. on February 11, 2020.
お知らせ • Jun 19EastWest Bioscience Inc. announced that it expects to receive CAD 0.1 million in fundingEastWest Bioscience Inc. (TSXV:EAST) announced a private placement of up to 2,000,000 common shares at an issue price of CAD 0.05 per share for gross proceeds of up to CAD 100,000 on June 18, 2020. All securities issued in the transaction have a hold period of 4 months. The transaction is subject to approval from TSX Venture Exchange.
